TPST

Tempest Therapeuticsdistress 10/10 · high distress / dilution risk

$0.96+1%today-92% from 52w high

tempesttx.com5 employeesBrisbane, CABiotechnology

Lead: r/r multiple myeloma · est. market ~$25B (approx, global)

Revenue

pre-revenue

Liquidity

$2M

Runway

0.1 yrs

Shares 1y

+234%

Price & events

-68.8% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.7%

-1.9%

-23.7%

-46.8%

-67.9%

-84.7%

-96.0%

-99.5%

-99.8%

All

Overview

Market Cap: $14.18M
Enterprise Value: $16.57M
Volume: 267.10K
52 Week Range: $0.95 – $11.83
Total Shares: 14.81M
Float Shares: 9.73M
Short %: 3.81%
% Held by Insiders: 31.78%
% Held by Institutions: 26.40%
RVOL: 1.46x
Beta: -1.71

Pipeline stages · 1 programs

TPST-1120, Atezolizumab, Bevacizumab

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-12

Pipeline · 1 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2028-12 Estimated 50% readout ~2029-02-14	Phase 3	TPST-1120, Atezolizumab, Bevacizumaborphan	Hepatocellular Carcinoma (HCC)	—	not yet recruiting

Catalyst news & presentations · 12

2027Guided 40%regulatory submissionFiled (NDA/BLA)TPST-2003 · Plan to submit BLA in China in 2027SEC 8-K
2026Guided 40%trial initiationsecondaryTPST-2003 · Initiate U.S. registrational studySEC 8-K
2026Guided 40%regulatory submissionFiled (NDA/BLA)TPST-2003 · Submit U.S. IND for TPST-2003SEC 8-K
Data from Phase 1 dose expansion expected 2026Guided 40%readoutPhase 1TPST-2003 · Phase 1 dose expansion data expected 2026SEC 8-K
2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
2026-07-17partnershipTPST-4003 · Product development and IIT collaboration with Senlang Biotechnology for TPST-4003 in China.SEC 8-K
Q2 2026readoutPhase 1TPST-2206 · Phase 1 China interim data readoutSEC 8-K
Phase 2b IIT and Phase 1 (China) resultsreadoutPhase 1/2TPST-2003 · Phase 2b IIT and Phase 1 results expected Q1 2026SEC 8-K
2025-11-19partnershipAsset purchase agreement for four CAR-T therapies (ERI-2003, ERI-2206, ERI-3003, ERI-3206)SEC 8-K
2025-06-11withdrawalSuspended and terminated the ATM prospectus for common stock sales under Sales Agreement with Jefferies.SEC 8-K
2024-10-07partnershipamezalpat (TPST-1120) · Master clinical supply agreement with Roche to supply atezolizumab for combination studies.SEC 8-K
planned phase 3 trialtrial initiationsecondaryPhase 3amezalpat (TPST-1120) · Phase 3 randomized, double-blind, placebo-controlled study of TPST-1120 in combination with atezolizumab plus bevacizumab compared with placebo plus atezolizumab plus bevacizumab.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 14,806,997 · 4 offerings/1y · 5 PIPEs

2026-07-08424B3offering
2026-07-07EFFECTshelf_effective
2026-06-26S-3shelf_registration
2026-06-028-Kprivate_placement
2026-04-10424B3offering
2026-04-10424B3offering
2026-04-09EFFECTshelf_effective

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2026-01-22HC Wainwright & Co.Neutral → Buy
2025-04-10ScotiabankSector Outperform → Sector Perform
2025-04-10HC Wainwright & Co.Buy → Neutral
2025-03-28ScotiabankSector Outperform
2025-03-28HC Wainwright & Co.Buy
2024-11-13Piper SandlerOverweight

Competitors — r/r multiple myeloma

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.